Braveheart Bio, Inc. (NASDAQ:BRVE) Stock Has Consensus Target Price of $45.25 According to Brokerages

Posted by George Bondi on Oct 27th, 2026

Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report) has received an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $45.25.

A number of research firms recently weighed in on BRVE. Stifel Nicolaus initiated coverage on Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating and a $45.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $40.00 price objective on shares of Braveheart Bio in a research note on Tuesday, October 20th. Wall Street Zen raised Braveheart Bio to a “hold” rating in a research note on Saturday, August 15th. Jefferies Financial Group assumed coverage on Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating and a $48.00 target price on the stock. Finally, TD Cowen initiated coverage on Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating for the company.

Get Our Latest Stock Report on BRVE

Braveheart Bio Trading Up 2.0%

NASDAQ:BRVE opened at $21.87 on Tuesday. Braveheart Bio has a 12 month low of $17.86 and a 12 month high of $32.00. The company has a 50-day moving average price of $24.11.

Braveheart Bio (NASDAQ:BRVE – Get Free Report) last posted its quarterly earnings data on Tuesday, September 8th. The company reported ($2.51) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($2.26). Research analysts predict that Braveheart Bio will post -1.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Braveheart Bio

In related news, major shareholder Growth Opportunities F. Forbion acquired 1,920,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were purchased at an average price of $18.00 per share, with a total value of $34,560,000.00. Following the acquisition, the insider directly owned 11,640,546 shares in the company, valued at $209,529,828. The trade was a 19.75% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Bio Fund Iv L.P. Ah acquired 1,100,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $19,800,000.00. Following the acquisition, the insider owned 10,232,420 shares in the company, valued at approximately $184,183,560. The trade was a 12.05% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 8,751,942 shares of company stock worth $157,534,956 over the last quarter.

Braveheart Bio Company Profile

(Get Free Report)

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.